ClinicalTrials.gg
CompletedNCT05843539CAPONEUpdated Jul 22, 2025

Adverse Childhood Experiences, Adaptation and Breast Cancer

An observational study in Adverse Childhood Experiences, Cancer, Breast and Attachment Styles, sponsored by University of Lorraine. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by University of Lorraine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,209 studies in Breast Neoplasms with a site in France — 207 open to participants now, 339 under way, 83 of them phase 3. Breast Neoplasms · France.

Enrollment
140th of 203
100 · median 200
Started
2022
with 61 others
Observational
204 of 1,209
44 open now
Registered
1,016th of 1,209
by date

Among the 1,209 studies in Breast Neoplasms with a site in France, this one is the 140th largest by enrollment of the 203 observational ones that give a count, is one of 62 that started in 2022, is one of 204 observational ones, and was the 1,016th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

207 of the 1,209 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

202 more — sign in →

All 207 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,209 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

Adverse Childhood Experiences (ACEs) have long been linked to mental health problems in adulthood. In the case of cancer, no study has considered that such an anteriority could make patients more vulnerable emotionally, even though the presence of reactionary disorders such as stress, anxiety or depression are characteristic of such a pathology. Activated during periods of stress and therefore during the illness, even the attachment system is mobilized and must be considered to allow more understanding of the illness experience. The attachment style can be seen here as an individual dimension that plays a role in the emotional regulation and resilience of patients. It is also particularly solicited during the remission phase, a complex and singular period of cancer disease that confronts patients with an ambivalence of hope and fear. The fear of recurrence is a concern that the cancer may return or progress in the same organ or in another part of the body. This is a determining factor in the occurrence of anxiety-depressive disorders. Finally, several studies have shown a strong association between depression/anxiety and Cancer-Related Fatigue (CRF) after treatment, especially during the remission phase.

ACEs leave physiological and epigenetic impact that can nowadays be easily evaluated, thus providing additional evidence between adversity, physiological and epigenetic vulnerability and the ability to adapt to life's challenges such as cancer. Life history changes are mediated by changes in cellular mechanisms affecting genome expression. It is currently widely demonstrated that ACEs increases epigenetic modifications.

The interest of this project is therefore to highlight the psychological consequences related to the occurrence of cancer in the developmental history (in terms of adversities) of patients who have completed adjuvant chemotherapy for breast cancer, taking into account the patients' previous attachments, resilience, fear of recurrence and perceived fatigue in order to consider their interactions and their effects on their psychological health and ultimately on their quality of life.

03

Conditions studied

  • Adverse Childhood Experiences
  • Cancer, Breast
  • Attachment Styles
  • Resilience, Psychological
  • Quality of Life
  • Epigenesis, Genetic

Browse trials for

Keywords

  • Breast Cancer
  • ACEs
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population studied in this research is a group of adult women who have had breast cancer and are in remission, i.e. whose symptoms and clinical signs visible on medical imaging have diminished or disappeared after treatment for the cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had breast cancer
  • Be considered in remission
  • Be over 18 years of age
  • Literate (able to understand the information and complete the questionnaire independently)
  • Agree to participate in the project and sign the form

Exclusion criteria

Exclusion Criteria:

  • Be a person subject to a legal protection measure
  • Be a protected adult, under guardianship or curators
  • Be undergoing oncological treatment
  • Have a lack of autonomy making it impossible to complete the questionnaire online
  • Have had or have begun psychotherapeutic treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • GeneticBiological and epigenetic measures

    This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.

06

What researchers measure

Primary outcomes

  1. Quality of life of women in remission from breast cancer

    The primary outcome was quality of life assessed with the Short Form Survey 12 (SF-12 scale). The score ranges from 0 to 100, with a score above 50 indicating average quality of life, 40 to 49 indicating mild disability, 30 to 39 indicating moderate disability, and below 30 indicating severe disability.

    Time frame: Baseline. Through study completion, an average of 1 year.

Secondary outcomes

  1. Fear of recurrence

    The level of fear of cancer recurrence as assessed by the Cancer Recurrence Fear Inventory

    Time frame: Baseline. Through study completion, an average of 1 year.

  2. Fatigue

    Level of fatigue assessed by the Multidimensional Fatigue Inventory (MFI). It is a questionnaire with 20 items on a 5-point likert scale ranging from 1 "strongly disagree" (worth 1 point) to 5 "strongly agree" (worth 5 points). The score is calculated by summing the points on the scale. The higher the score, the more severe the fatigue.

    Time frame: Baseline. Through study completion, an average of 1 year.

  3. Anxiety and Depression

    Level of anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS). This scale evaluates the level of anxiety in 7 items and the level of depression in 7 items, ranging from 0 to 3. A score greater than or equal to 10 indicates a definite level of anxiety or depression.

    Time frame: Baseline. Through study completion, an average of 1 year.

  4. Attachment

    Attachment relationships were assessed using the Relationship Scales Questionnaire (RSQ).

    Time frame: Baseline. Through study completion, an average of 1 year.

  5. Adverse Childhood Experiences

    The number of adverse childhood and adolescent experiences assessed using the Adverse Childhood Experiences International Questionnaire (ACE-IQ). The total number of ACEs to which the participant has been "exposed" is summed to create an ACE score ranging from 0 (no ACEs) to 13. A score of 0 ACEs means a low level of adversity and a score of 13 means a major level of adversity.

    Time frame: Baseline. Through study completion, an average of 1 year.

  6. Resilience

    The level of resilience estimated using the Brief Resilience Scale (BRS). The Brief Resilience Scale is a 6-item questionnaire. Each item is rated on a 5-point Likert scale. Higher scores indicate greater resilience.

    Time frame: Baseline. Through study completion, an average of 1 year.

  7. RMSSD values

    Differences in resting RMSSD (root mean square of successive differences between normal heartbeats) values according to the status with or without ACE, performed via the Caducy (software)

    Time frame: Baseline. Through study completion, an average of 1 year.

Other outcomes

  1. Stress measurement

    Hair cortisol levels via analysis of 100 hairs collected with the root and stored at 4°C

    Time frame: Baseline. Through study completion, an average of 1 year.

  2. Measurement of epigenetic methylations in relation to childhood adversity

    Percentage methylation of genes coding for directed analysis of target regions coding for NR3C1 and FKBP5 genes derived from whole blood, saliva and oral cells assessed using chromatin immunoprecipitation (ChIP) assays

    Time frame: Baseline. Through study completion, an average of 1 year.

07

Study locations

1 site
  • Ur 4360 Apemac
    Metz, Lorraine 57000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jun 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
May 6, 2023
StartActual
Apr 12, 2022
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843539
Lead sponsor
University of Lorraine
Collaborators
Ligue contre le cancer, France
Responsible party
Christine Rotonda (Director of the research pole in Pierre Janet Center, University of Lorraine) — Principal investigator
First posted
May 6, 2023
Start date
Apr 12, 2022
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Jul 22, 2025

Study contacts

Marion Trousselard, Pr
principal investigator · UR 4360 APEMAC, University of Lorraine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion